Ventilator Associated Tracheobronchitis – Etiology and Outcome at an Intensive Care Unit of a Tertiary Care Center in North India

Kakati, Barnali; Koul, Nupur; Agarwal, Sonika

doi:10.30699/ijmm.17.1.103

year 17, Issue 1 (January - February 2023) Iran J Med Microbiol 2023, 17(1): 103-106 | Back to browse issues page

‎ 10.30699/ijmm.17.1.103

Mendeley

Zotero

RefWorks

Kakati B, Koul N, Agarwal S. Ventilator Associated Tracheobronchitis – Etiology and Outcome at an Intensive Care Unit of a Tertiary Care Center in North India. Iran J Med Microbiol 2023; 17 (1) :103-106
URL: http://ijmm.ir/article-1-1668-en.html

Ventilator Associated Tracheobronchitis – Etiology and Outcome at an Intensive Care Unit of a Tertiary Care Center in North India

Barnali Kakati¹

, Nupur Koul

², Sonika Agarwal³

1- Department of Microbiology, Himalayan Institute of Medical Sciences, Swami Rama Himalayan University (SRHU), Dehradun, India
2- Department of Microbiology, Himalayan Institute of Medical Sciences, Swami Rama Himalayan University (SRHU), Dehradun, India , nupurba88@gmail.com
3- Department of Critical Care Medicine, Himalayan Institute of Medical Sciences, Swami Rama Himalayan University (SRHU), Dehradun, India

Abstract: (1775 Views)

Background and Aim: Ventilator associated Tracheobronchitis (VAT) is a common nosocomial respiratory tract infection which develops in intubated critically ill patients. Their etiology changes with time, hospital and ICU setting and duration of hospital stay. This study was aimed at detecting the microbiological etiology of VAT, reporting the antimicrobial susceptibility pattern and impact on outcome.
Materials and Methods: This observational study was conducted for 12 months in the Microbiology Department and intensive care unit of a tertiary care center. A total of 39 endotracheal secretions from suspected cases of VAT were subjected to routine bacterial culture and antimicrobial susceptibility testing. The outcome of the patients with VAT was measured in terms of duration of ventilation, hospital stay and mortality.
Results: VAT was found to occur most commonly between 60-69 years of age and among the male population (79%). A total of 47 isolates were recovered from 39 samples. Monomicrobial growth was obtained from 34 (87.18%) of endotracheal samples, while 5 (12.82%) showed polymicrobial growth of at least two pathogens. The predominant organism isolated was Acinetobacter baumannii (27.65%), followed by Klebsiella pneumoniae (23.40%) and Pseudomonas aeruginosa (21.27%) and all were found to be multidrug resistant. The mean duration of ventilation, ICU Stay and hospital stay for VAT was 10.87 days, 12.20 and 16.27 respectively.
Conclusion: It is imperative to timely diagnose and monitor cases of VAT as this would help in deriving an effective early therapeutic intervention and in implementing timely preventive strategies that could help reduce progression of VAT to Ventilator associated pneumonia (VAP).

Keywords: Ventilator associated Tracheobronchitis (VAT), Ventilator associated Pneumonia (VAP), multidrug resistance (MDR), Endotracheal secretion

Full-Text [PDF 452 kb] (577 Downloads) | | Full-Text (HTML) (381 Views)

Type of Study: Brief Original Article | Subject: Medical Bacteriology
Received: 2022/02/10 | Accepted: 2022/07/6 | ePublished: 2023/01/20

References

1. Thiéry G, Kovacević P, Straus S, Vidovic J, Iglica A, Festic E, et al. From mechanical ventilation to intensive care medicine: a challenge for Bosnia and Herzegovina. Bosn J Basic Med Sci. 2009;9 Suppl 1:69-76. [DOI:10.17305/bjbms.2009.2766] [PMID]

2. Phu VD, Nadjm B, Duy NHA, Co DX, Mai NTH, Trinh DT, et al. Ventilator-associated respiratory infection in a resource-restricted setting: impact and etiology. J Intensive Care. 2017;5:69. [DOI:10.1186/s40560-017-0266-4] [PMID] [PMCID]

3. Ray U, Ramasubban S, Chakravarty C, Goswami L, Dutta S. A prospective study of ventilator-associated tracheobronchitis: Incidence and etiology in intensive care unit of a tertiary care hospital. Lung India. 2017;34(3):236-40. [DOI:10.4103/lungindia.lungindia_134_15] [PMID] [PMCID]

4. Craven DE, Hjalmarson KI. Ventilator-associated tracheobronchitis and pneumonia: thinking outside the box. Clin Infect Dis. 2010;51 Suppl 1:S59-66. [DOI:10.1086/653051] [PMID]

5. Amin A. Clinical and economic consequences of ventilator-associated pneumonia. Clin Infect Dis. 2009;49 Suppl 1:S36-43. [DOI:10.1086/599814] [PMID]

6. Chastre J, Fagon JY. Ventilator-associated pneumonia. Am J Respir Crit Care Med. 2002;165(7):867-903. [DOI:10.1164/ajrccm.165.7.2105078] [PMID]

7. Nseir S, Di Pompeo C, Pronnier P, Beague S, Onimus T, Saulnier F, et al. Nosocomial tracheobronchitis in mechanically ventilated patients: incidence, aetiology and outcome. Eur Respir J. 2002;20(6):1483-9. [DOI:10.1183/09031936.02.00012902] [PMID]

8. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. 2018.

9. Rajasekhar T, Anuradha K, Suhasini T, Lakshmi V. The role of quantitative cultures of non-bronchoscopic samples in ventilator associated pneumonia. Indian J Med Microbiol. 2006;24(2):107-13. https://doi.org/10.4103/0255-0857.25226 [DOI:10.1016/S0255-0857(21)02408-7] [PMID]

10. Nseir S, Di Pompeo C, Soubrier S, Lenci H, Delour P, Onimus T, et al. Effect of ventilator-associated tracheobronchitis on outcome in patients without chronic respiratory failure: a case-control study. Crit Care. 2005;9(3):R238-45. [DOI:10.1186/cc3508] [PMID] [PMCID]